The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease

Diabetes and Metabolism

Volumn 29, Issue 6, 2003, Pages 613-618

  Paragh, G ^a   Seres, I ^a   Harangi, M ^a   Balogh, Z ^a   Illyes L ^b   Boda, J ^a   Szilvassy Z ^a   Kovacs P ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Department of Rehabilitation Semmelweis Teaching Hospital Szent Ferenc Hospital Division   (Hungary)

Author keywords

Coronary Heart Disease; Hyperlipidemia; Micronised Fenofibrate; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLDIALKYLPHOSPHATASE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 2; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; TREATMENT PLANNING;

EID: 0345862181     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70077-0     Document Type: Article

References (34)

1. Brown MS, Goldstein IL. Scavenging for receptors. Nature, 1990, 343, 508-9.
2. Kannel WB, Dawber TR, Friedman GD. Risk factors in Coronary Heart Disease. An evaluation of several serum lipids as predictors of coronary heart disease: The Framingham Study. Ann Intern Med, 1964, 61, 888-99.
3. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: Risk factor changes and mortality result. JAMA, 1982, 248, 1465-77.
4. Assmann G, Schulte. H. Relation of high density lipoprotein cholesterol and triglycerides to atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol, 1992, 70, 733-7.
5. Bainton D, Miller NE, Bolton CH, et al. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J, 1992, 68, 60-6.
6. Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J, 1986, 112, 432-7.
7. Guichard JP, Prades Sauron RL. A comparison of the bioavaibbility of standard or micronized formulations of fenofibrate. Curr Ther Res, 1993, 54, 610.
8. SchierfG, Shwat M, Feuerborn E. Biliary and plasma lipids and lipid-lowering chemotherapy. Studies with clofibrate, fenofibrate and etofibrate in healthy volunteers. Atherosclerosis, 1980, 36, 323-9.
9. Franceschini G. Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. Am J Cardiol, 2001, 88(Suppl), 9N-13N.
10. Assmann G, Eckardstein A, Nofer JR, et al. Role of HDL in reverse cholesterol transport. Atherosclerosis, 1999, 146, S1.
11. Fogelman AM, Schechter JS, Hoko M. Malondialdehyde alteration of low density lipoprotein leads to cholesterol accumulation in human monocyte-macrophages. Proc Natl Acad Sci, USA, 1980, 77, 2214-8.
12. Mahley RW, Innerarity TL, Weisgraber KH. Altered metabolism (in vivo and vitro) of plasma lipoprotein after selective chemical modification of lysine residues of the apoproteins. J Clin Invest, 1979, 64, 743-50.
13. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation, 1992, 70, 733-7.
14. Paragh G, Balogh Z, Seres I, et al. Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patients with hyperlipidaemia. Clin Drug Invest, 2000, 19, 277-82.
15. Abbott CA, Mackness MI, Kumar S, et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol, 1995, 15, 1812-8.
16. Paragh Gy, Asztalos L, Seres I, et al. Serum paraoxonase activity changes in uremic and kidney transplanted patients. Nephron, 1999, 83, 126-31.
17. Eckerson HW, Romson J, Wyte C, La Du BN: The human serum paraoxonase polymorphism: identification of phenotypes by their response to salts. Am J Hum Genet, 1999, 35, 214-27.
18. Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet, 1983, 35, 1126-38.
19. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med, 1987, 83, 9-20.
20. Blane GF. Review of European clinical experience with fenofibrate. Cardiology, 1989, 76, 1.
21. Kornitzer M, Dramaix M, Vandenbrock MD, et al. Efficacy and tolerance of 200 mg micronised fenofibrate administered over a 6-month period in hyperlipidaemic patients: an open Belgian multicenter study. Atherosclerosis, 1994, 110, S49-S54.
22. Auwerx, J, Schoonjans K, Fruchart JC, et al. Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR. Atherosclerosis, 1996, 124, S29-S37.
23. Kashyap MI, Saku K. HDL metabolism in HDL deficiency, associated with familial hypertriglyceridaemia: effect of gemfibrozil. Adv Exp Med Biol, 1991, 285, 233-6.
24. Branchi A, Rovellini A, Sommariva D. Differential effects of sinivastatin and bezafibrate on apolipoprotein-defined high-denisty lipoprotein subfractions in patients with hypercholesterolemia. Curr Ther Res, 1996, 57, 26-32.
25. Branchi A, Rovellini A, Sommariva D. Effect of bezafibrate on HDL with apo A-I and apo A-II on HDL with apo A-I without apo A-II in hypedipidaemic patients. Int J Clin Pharmacol Res, 1995, 15, 153-8.
26. Gordon T, Castelli W, Hjörtland MC. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med, 1977, 62, 707-14.
27. Brown WV, Dujovne CA, Farquhar JW, et al. Effects of fenofibrate on plasma lipids: double-blind, multicenter study in patients with type IIa or IIb hyperlipidemia. Atherosclerosis, 1986, 6, 670.
28. Mackness MI, Abbott CA, Arrol S, et al. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J, 1993, 294, 829-35.
29. La Du BN, Eckerson HW. The polymorphic paraoxonase/arylesterase isoenzymes of human serum. Federation Proc, 1984, 43, 2338-41.
30. Heinecke JW, Lusis AJ. Paraoxonase-gen polymorphisms associated with coronary heart disease: support for oxidative damage hypothesis? Am J Hum Genet, 1998, 62, 20-4.
31. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholcsterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis, 1991, 86, 193-9.
32. McElveen J, Mackness MI, Colley CM, et al. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem, 1986, 32, 671-3.
33. Paragh G, Seres I, Balogh Z, et al. The serum paraoxonase activity in patients with chronic renal failure and hyperlipidemia. Nephron, 1998, 80, 166-70.
34. Durrington PN, Mackness MI, Bhatnagar D, et al. Effects of two different fibric acid derivates on lipoproteins, cholesterol ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in Type IIb hyperlipoproteinaemia. Atherosclerosis, 1998, 138, 217-25.